Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer, which originates from the mesothelial cells of the pleura and is associated with asbestos exposure. In light of its aggressive nature, late diagnosis and dismal prognosis, there is an urgent need for identification of biomarkers i...
Main Authors: | Luca Ferrari, Michele Carugno, Carolina Mensi, Angela Cecilia Pesatori |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00445/full |
Similar Items
-
Editorial: Epigenetic Modifications in Mesothelioma
by: Yuen Yee Cheng, et al.
Published: (2021-02-01) -
The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
by: Eric Rozitis, et al.
Published: (2020-09-01) -
Circulating biomarkers in malignant pleural mesothelioma
by: Giuseppe Viscardi, et al.
Published: (2020-12-01) -
5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin
by: Matteo Bosio, et al.
Published: (2018-08-01) -
Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma
by: Vanessa Martínez-Rivera, et al.
Published: (2018-02-01)